Genotype Allele Population Type and size of the study Association OR / RR References
ERα351 Xbal A/G AA Norway 27 to 94 years-old Case / control 360/672 ↑ risk for breast cancer after menopause OR: 2.02 IC 95%: 0.96-4.31 Andersen et al. [18]
  AA Korea Case / control 205/205 ↑ risk for breastcancer OR: 2.38 IC 95%: 1.58-3.58 Shin et al.  [6]
  AA Korea Case / control 205/205 ↑ risk for breast cancer in nulliparous RR: 4.0 IC 95%: 1.9-8.8 Shin et al. [6]
  AA Netherlands and England After- menpausa Cohort prospective 791withHT / 781 no HT ↑mammographic density in HT users 2,20% p<0,01 vanDuijnhoven et al. [17]
  AA China   ↑ risk for breastcancer OR: 6.88 IC 95%: 0.80-59.15 p=0.079 Hu et al. [19]
  AA China 25-55 years-old Case / control ↑ risk for breast cancer, with positive family history OR: 4.20 IC 95%: 0.65-27.28 Shen et al.  [12]
  AA Netherlands 55 yearsor more Case / control 190/3513 ↑ risk for breast cancer in women after menopause OR: 1.3 IC 95%: 0.7-2.2 Ladd et al. [14]
  AA Brazil After -menopause Prospective 120 ↑ higherbreastdensity OR: 2.34 IC95%:1.06-5.16 p=0.03 Ramos et al. [20]
    England Systematic review of case-control studies Nonsignificantdifference P=0,06 Dunning et al. [21]
  AA Pakistan, 15-65 years-old Case / control 100/100 ↑ of the risk of BC post menopouse  AA 45% greater than GG p<0.01 Javed et al.  [22]
  AA BrazilAfter -menoppausa Only cases 308 women Mammographicdensity> 50% AA 33,44% greaterthan GG 16,56% Souza et al. [16]
HaplotypXbal -C975→G   SwedenAfter- menoppausa Case / control 1556/1512 ↑ risk of breast cancer in postmenopausal and obese women OR=1,48 IC 95%: 1,17-1,88 Wedren et al. [23]
  AG Norway 27-94 years-old Case / control 360/672 ↑ risk for breastcancer OR: 2.00 IC 95%: 0.92-4.37 Andersen et al. [18]
  GG USA, Caucasian greater than 65 years-old Case / control 393/790 ↓ risk for breastcancer OR 0.82 IC 95%: 0.68-1.00 P= 0.04 Wang et al. [24]
  GG Netherlands and England After- menopause Prospective Cohort 795 with HT / 781 no HT Mammographic density without changes in users of HT 0,65% p= 0.70 van Duijnhoven et al.[17]
  A China Case / control 114/121 ↑ risk for breastcancer OR: 1.4 IC 95%: 1.0-1.9 Hu et al. [19]
  G Korea Case / control 205/205 ↓ risk for breast cancer in postmenopausal RR: 0.3 IC 95%: 0.1-0.5 Shin et al. [6]
Table 2: Association studies of the ERα-351 XbaI A/G gene polymorphism with BC and/or risk factors for disease.